<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749136</url>
  </required_header>
  <id_info>
    <org_study_id>AsanONCHBP-2015-001</org_study_id>
    <nct_id>NCT02749136</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer</brief_title>
  <official_title>Phase 2 Study of Neoadjuvant Modified FOLFIRINOX in Patients With Borderline Resectable Pancreas Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility and efficacy outcomes of neoadjuvant
      modified FOLFIRINOX and postoperative gemcitabine in patients with borderline resectable
      pancreatic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer is the fourth leading cause of cancer-related death worldwide. The 5-year
      survival rate in overall patients is less than 6% due to late clinical manifestation and the
      systemic nature of the disease at presentation. Even in patients with resectable disease,
      estimated 5-year survival rates after resection are between 15% and 20%. Traditionally,
      resection alone is regarded as inadequate for cure. Therefore, systemic and/or combined
      chemotherapy and radiotherapy have been used as preoperative or postoperative therapy.

      Neoadjuvant treatment offers several theoretical advantages over an initial resection. Early
      delivery of systemic therapy for all patients which might lead to the higher rates of
      negative margin resection rate, and enhanced patient selection for surgery. Although
      neoadjuvant treatment has been established as a standard of care for resectable or locally
      advanced disease of breast, gastric, and rectal cancers, the role of neoadjuvant treatment in
      patients with pancreatic cancer is not clear at present.

      There is no global consensus on the management of patients with borderline resectable
      pancreatic cancer. If initially resected, postoperative adjuvant chemotherapy or
      chemoradiotherapy is standard. However, there is no standard regimen for neoadjuvant
      chemotherapy for pancreatic cancer. Recent pivotal phase 2/3 trial has demonstrated that
      FOLFIRINOX improved the response rates and survival outcomes of patients with metastatic
      pancreatic cancer compared to gemcitabine.

      Because of higher response rates (about 30%) with FOLFIRINOX, this regimen is now widely
      investigated in the neoadjuvant setting. Therefore, investigators hypothesize that
      neoadjuvant FOLFIRINOX may enhance the outcomes of patients with borderline resectable
      pancreatic cancer. This study will assess the feasibility and efficacy outcomes of
      neoadjuvant modified FOLFIRINOX and postoperative gemcitabine in patients with borderline
      resectable pancreatic cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year progression-free survival (PFS) rate</measure>
    <time_frame>1 year</time_frame>
    <description>PFS rate at 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Median PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Median OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macroscopic complete resection rate</measure>
    <time_frame>5 months</time_frame>
    <description>The rate of no gross residual disease after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 months</time_frame>
    <description>Response rate defined by Response Evaluation Criteria in Solid Tumor version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events graded by National Cancer Institute Common Terminology Criteria version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>3 years</time_frame>
    <description>Blood-based biomarker analysis for the correlation with response rate, progression-free survival and overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Perioperative chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles
Postoperative gemcitabine, every 4 weeks, 3-6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preoperative modified FOLFIRINOX and postoperative gemcitabine</intervention_name>
    <description>Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles
Oxaliplatin IV 85 mg/m2 Day (D) 1
Irinotecan IV 180 mg/m2 D1
5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2
Leucovorin IV 400 mg/m2 D1
Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15</description>
    <arm_group_label>Perioperative chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 19 years and older

          -  Cytologically or histologically confirmed adenocarcinoma of the pancreas

          -  Met the NCCN criteria for borderline resectable disease (assessed at Aug 23rd, 2015)

          -  No previous chemotherapy or radiotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 ~ 1

          -  Adequate bone marrow function as defined by platelets ≥ 100 x 109/L and neutrophils ≥
             1.5 x 109/L

          -  Adequate renal function, with serum creatinine &lt; 1.5 x upper limit of normal (ULN)

          -  Adequate hepatic function with serum total bilirubin &lt; 2 mg/dL, alanine
             aminotransferase (ALT) or aspartate aminotransferase (AST) &lt; 2.5 x ULN

          -  No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ
             of the uterine cervix or any other non life-threatening cancer (i.e., prostate or
             thyroid cancer) except where treated with curative intent &gt; 5 years previously without
             evidence of relapse

          -  Written informed consent to the study

        Exclusion Criteria:

          -  No potentially resectable disease or no metastatic disease

          -  Locally advanced unresectable disease according to the NCCN criteria

          -  Histologically confirmed adenosquamous carcinoma

          -  Medical or psychiatric conditions that compromise the patient's ability to give
             informed consent or to complete the protocol or a history of non-compliance

          -  Last dose of radiotherapy received within 4 weeks before the start of study treatment,
             excluding palliative radiotherapy

          -  Obstruction of gastrointestinal tract

          -  Active gastrointestinal bleeding

          -  Myocardial infarction within 6 months prior to the study medication, and other
             clinically significant heart disease (e.g., unstable angina, congestive heart failure
             or uncontrolled hypertension)

          -  Evidence of severe or uncontrolled systemic disease or any concurrent condition which
             in the investigator's opinion makes it undesirable for the patient to participate in
             the study or which would jeopardise compliance with the protocol

          -  Female subjects who are pregnant or lactating, or males and females of reproductive
             potential not willing or not able to employ a highly effective method of birth
             control/contraception to prevent pregnancy from 2 weeks before receiving study drug
             until 3 months after receiving the last dose of study drug. A highly effective method
             of contraception is defined as having a low failure rate (&lt; 1% per year) when used
             consistently and correctly.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baek-Yeol Ryoo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baek-Yeol Ryoo, MD, PhD</last_name>
    <phone>+82-2-3010-3211</phone>
    <email>ryooby@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Changhoon Yoo, MD</last_name>
    <phone>+82-10-9900-6798</phone>
    <email>yooc@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center, University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changhoon Yoo, MD</last_name>
      <phone>+82-2-3010-1727</phone>
      <email>yooc@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, Kindler HL, Alberts SR, Philip P, Lowy AM, Pisters PW, Posner MC, Berlin JD, Ahmad SA. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013 Aug;20(8):2787-95. doi: 10.1245/s10434-013-2886-9. Epub 2013 Feb 23. Review.</citation>
    <PMID>23435609</PMID>
  </reference>
  <reference>
    <citation>OʼReilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP, DʼAngelica M, Kurtz RC, Abou-Alfa GK, Klimstra DS, Lowery MA, Brennan MF, Coit DG, Reidy DL, Kingham TP, Allen PJ. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014 Jul;260(1):142-8. doi: 10.1097/SLA.0000000000000251.</citation>
    <PMID>24901360</PMID>
  </reference>
  <reference>
    <citation>Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. 2013 Oct;24(10):2484-92. doi: 10.1093/annonc/mdt239. Epub 2013 Jul 12. Review.</citation>
    <PMID>23852311</PMID>
  </reference>
  <reference>
    <citation>Lee JL, Kim SC, Kim JH, Lee SS, Kim TW, Park DH, Seo DW, Lee SK, Kim MH, Kim JH, Park JH, Shin SH, Han DJ. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery. 2012 Nov;152(5):851-62. doi: 10.1016/j.surg.2012.03.010. Epub 2012 Jun 6.</citation>
    <PMID>22682078</PMID>
  </reference>
  <reference>
    <citation>Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015 Jun 1;33(16):1770-8. doi: 10.1200/JCO.2014.59.7930. Epub 2015 Apr 27. Review.</citation>
    <PMID>25918279</PMID>
  </reference>
  <reference>
    <citation>Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17;297(3):267-77.</citation>
    <PMID>17227978</PMID>
  </reference>
  <reference>
    <citation>Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8;304(10):1073-81. doi: 10.1001/jama.2010.1275.</citation>
    <PMID>20823433</PMID>
  </reference>
  <reference>
    <citation>Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.</citation>
    <PMID>21561347</PMID>
  </reference>
  <reference>
    <citation>Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, George B. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014 Mar;19(3):266-74. doi: 10.1634/theoncologist.2013-0273. Epub 2014 Feb 25.</citation>
    <PMID>24569947</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>March 8, 2017</last_update_submitted>
  <last_update_submitted_qc>March 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Baek-Yeol Ryoo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreatic adenocarcinoma</keyword>
  <keyword>Borderline resectable</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>FOLFIRINOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

